Alessandro Sessa
@alesessa.bsky.social
Neuroscientist and developmental biologist, head of the Neuroepigenetics Unit at San Raffaele Scientific Institute. Scientific founder of Repron Thx
Here the ESF based on SOX2 DNA binding activity www.science.org/doi/10.1126/.... This technology is now the core business of the spin-off company Repron therapeutics (www.reprontherapeutics.com/).5/n
A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development
The SOX2 epigenetic silencer (SES) is a synthetic GBM inhibitor factor that represses the SOX2 oncogenic transcriptional network.
www.science.org
December 2, 2024 at 3:37 PM
Here the ESF based on SOX2 DNA binding activity www.science.org/doi/10.1126/.... This technology is now the core business of the spin-off company Repron therapeutics (www.reprontherapeutics.com/).5/n
On the other side of the lab, we are developing epigenetic silencer factors which, acting as dominant negative counterpart of oncogenic TFs, induce the death of tumor cells in cell-autonomous fashion. 4/n
December 2, 2024 at 3:37 PM
On the other side of the lab, we are developing epigenetic silencer factors which, acting as dominant negative counterpart of oncogenic TFs, induce the death of tumor cells in cell-autonomous fashion. 4/n
See for example our works of Schinzel-Giedion syndrome www.nature.com/articles/s41... and www.nature.com/articles/s41.... 3/n
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome - Nature Communications
Schinzel-Giedion syndrome (SGS) is a fatal developmental syndrome characterized by severe intellectual and physical deficits due, at least in part, to early neurodegeneration. Here the authors introdu...
www.nature.com
December 2, 2024 at 3:37 PM
See for example our works of Schinzel-Giedion syndrome www.nature.com/articles/s41... and www.nature.com/articles/s41.... 3/n
Regarding the first topic, we are active in creating experimental models useful to both better understand the physiopathology of the diseases and as platform to test new treatments. 2/n
December 2, 2024 at 3:37 PM
Regarding the first topic, we are active in creating experimental models useful to both better understand the physiopathology of the diseases and as platform to test new treatments. 2/n